1. home
  2. #tags
  3. Securities

Discover Latest #Securities News, Articles and Videos with Contenting

Securities news and articles provide information on the stock market, investments, and other financial matters. They often include commentary and analysis from financial experts. Videos can also provide helpful information on financial matters, such as stock market trends, investment strategies, and economic news. Reading securities news and watching videos can help investors stay informed and make better decisions about their investments.

Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds - ForexTV

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – June 25, 2025Idorsia Ltd (SIX: IDIA) today announced the launch of the repurchase offer to the holders of its outstanding CHF 200 million convertible bonds maturing in 2025 (CB 2025; ISIN CH0426820350), and CHF 600 million convertible bonds maturing in 2028 (CB 2028; ISIN CH1128004079) (the Repurchase Offer). The Repurchase Offer is part of a larger holistic restructuring, as announced in a press release on February 26, 2025, and an update published on May 21, 2025. To date, bondholders holding approximately 87.5% of the aggregate nominal value of the CB 2025 and approximately 90.1% of the aggregate nominal value of the CB 2028 have entered a legally binding lockup agreement in support of the holistic restructuring, including the Repurchase Offer. Such bondholders have committed to participating in the Repurchase Offer and to tender their CB 2025 and/or CB 2028 holdings. The main offer period of the Repurchase Offer is expected to start on July 10, 2025, and end at 17:30 hrs CEST on August 7, 2025. The Repurchase Offer is subject to certain offer conditions, as set out in the repurchase notice in relation to the Repurchase Offer (such notice, together with the other Repurchase Offer documentation (if any), the Repurchase Offer Documentation). These include a minimum acceptance rate condition, whereby at least 85% of the total issued nominal value of the CB 2025 and the CB 2028 must be validly tendered by the end of the main offer period of the Repurchase Offer. Bondholders can access the Repurchase Offer Documentation, including further information and instructions at the following link: www.idorsia.com/exchange-offer. Bondholders can participate in the Repurchase Offer and tender their CB 2025 and/or CB 2028 holdings via Kroll Issuer Services Ltd (the Agent) at the following link: https://deals.is.kroll.com/idorsia. Under the same link, eligible bondholders can (i) also participate in the new money facility via our Agent and (ii) find the eligibility criteria for participating in the new money facility. Further details regarding the interaction between participation in the new money facility and the Repurchase Offer can be found in the Repurchase Offer Documentation. Notes to the editor and legal notes About IdorsiaIdorsia Ltd is reaching out for more – we have more passion for science, we see more opportunities, and we want to help more patients. The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core. Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients. Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA). For further information, please contact:Investor & Media RelationsIdorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil+41 58 844 10 10investor.relations@idorsia.com – media.relations@idorsia.com – www.idorsia.com Legal Notice and InformationThe above information contains or may contain certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. The information contained in this media release is for information purposes only and does not constitute, or form part of, an offer or invitation to purchase, sell, exchange or issue, or a solicitation of an offer to sell, purchase, exchange or subscribe to, any securities of Idorsia Ltd or Idorsia Investments SARL, including without limitation the CB 2025 and the CB 2028, or any other person, nor shall it form the basis of, or be relied upon in connection with, any contract therefor. This media release is not part of the Repurchase Offer Documentation in relation to the Repurchase Offer. Terms and conditions of the Repurchase Offer have been and/or will be published in the Repurchase Offer Documentation. Holders of CB 2025 and/or CB 2028 are urged to read the Repurchase Offer Documentation, which is and/or will be available at www.idorsia.com/exchange-offer. This media release is not a financial product or investment advice, nor is it a recommendation to acquire, exchange or dispose of securities or accounting, legal or tax advice. It has been prepared without taking into account the objectives, legal, financial or tax situation and needs of individuals. Before making any investment decision, individuals should read the Repurchase Offer Documentation and consider the appropriateness of the information having regard to their own objectives, legal, financial and tax situation and needs and seek legal, tax and other advice as appropriate for their individual needs and jurisdiction. Offer RestrictionsThis media release is only intended for distribution to non-U.S. persons (within the meaning of Regulation S under the U.S. Securities Act of 1933, as amended). This media release is not an offer to tender securities or an offer of securities. The Repurchase Offer is being made on the basis of the Repurchase Offer Documentation only and is subject to the restrictions described therein. The Repurchase Offer is not being made, and will not be made, directly or indirectly in or into, or by use of the mails of, or by any means or instrumentality of interstate or foreign commerce of, or of any facilities of a national securities exchange of, the United States. This includes, but is not limited to, facsimile transmission, electronic mail, telex, telephone, the internet and other forms of electronic communication. Attachment Press Release PDF

Novartis announces expiration of Regulus Therapeutics tender offer - ForexTV

Basel, June 25, 2025 – Novartis today announced that its previously announced tender offer (the “Offer”) by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), to acquire all of the outstanding shares of common stock, par value $0.001 per share (the “Shares”), of Regulus Therapeutics Inc. (“Regulus”), in exchange for (i) $7.00 in cash per share, subject to any applicable withholding and without interest thereon, plus (ii) one contingent value right (each, a “CVR”) per Share, representing the right to receive one contingent payment of $7.00 in cash, subject to any applicable withholding and without interest thereon, upon the achievement of a regulatory milestone, expired at one minute past 11:59 p.m., New York City Time, on June 24, 2025 (the “Expiration Time”). Computershare Trust Company, N.A., the depositary for the Offer, has advised that, as of the Expiration Time, approximately 56,374,397 Shares were validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 74.49% of the issued and outstanding Shares immediately prior to the Expiration Time. The parties expect the transaction to close on June 25, 2025, promptly following the acceptance of all Shares validly tendered and not validly withdrawn pursuant to the Offer. Additional Information This press release is neither an offer to purchase nor a solicitation of an offer to sell any Shares or any other securities. At the time the tender offer described in this press release was commenced, Novartis and Purchaser filed a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and related documents, with the U.S. Securities and Exchange Commission (the “SEC”), and Regulus filed a solicitation/recommendation statement on Schedule 14D-9 with the SEC, in each case with respect to the tender offer. An offer to purchase the Shares is only being made pursuant to the offer to purchase, the letter of transmittal and related offer documents filed as a part of the Schedule TO. Those materials and all other documents filed by, or caused to be filed by, Novartis, Purchaser and Regulus with the SEC are available at no charge on the SEC’s website at www.sec.gov/ or by directing such requests to the information agent for the offer, which is named in the tender offer statement. The offer to purchase and related materials also may be obtained for free under the “Investors – Financial Data” section of Novartis website at www.novartis.com/investors/financial-data/sec-filings. The solicitation/recommendation statement also may be obtained for free under the “Investors” section of Regulus’ website at ir.regulusrx.com/overview. In addition, Regulus files annual, quarterly and current reports and other information, and Novartis files annual reports and other information with the SEC, which are also available to the public at no charge at www.sec.gov. Disclaimer This press release contains statements that are not statements of historical fact, or “forward-looking statements,” including with respect to Novartis’ proposed acquisition of Regulus. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for farabursen, regarding the proposed acquisition of Regulus and the expected timetable for completing the proposed acquisition, the benefits sought to be achieved in the proposed acquisition, or regarding potential future revenues from farabursen. You should not place undue reliance on these statements. Such forward-looking statements are based on Novartis’ current beliefs and expectations regarding future events and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that farabursen clinical trials will be successful, that farabursen will be submitted for marketing approval or approved for sale or, if approved, receive approval for any additional indications or labeling, in any market, or at any particular time, nor can there be any guarantee that, if approved, farabursen will be commercially successful in the future. Neither can there be any guarantee that the conditions to the closing of the proposed acquisition will be satisfied on the expected timetable or at all or that the expected benefits or synergies from this transaction will be achieved in the expected timeframe, or at all. In particular, expectations regarding farabursen or the transaction described in this press release could be affected by, among other things, the timing of the offer and the satisfaction of customary closing conditions, including the receipt of regulatory approvals on acceptable terms or at all; the risk that competing offers or acquisition proposals will be made; uncertainty as to whether the milestone associated with the CVR will be achieved and that holders of CVRs will receive payments in respect thereof; the effects of disruption from the transactions contemplated by the merger agreement and the impact of the announcement and pendency of the transactions on Novartis and/or Regulus’ businesses, including their relationships with employees, business partners or governmental entities; the risk that the offer or the merger may be more expensive to complete than anticipated; the risk that stockholder litigation in connection with the offer or the merger may result in significant costs of defense, indemnification and liability; a diversion of management’s attention from ongoing business operations and opportunities as a result of the offer, the merger or otherwise; general industry conditions and competition; general political, economic and business conditions, including interest rate and currency exchange rate fluctuations; the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s and Regulus’ filings and reports with the SEC, including Novartis AG’s Annual Report on Form 20-F for the year ended December 31, 2024, Regulus’ Annual Report on Form 10-K for the year ended December 31, 2024, Quarterly Report on Form10-Q for the quarter ended March 31, 2025 and any subsequent filings made by either party with the SEC, available on the SEC’s website at www.sec.gov. Novartis is providing the information in this press release as of this date and Novartis does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, except to the extent required by law. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. # # # Novartis Media RelationsE-mail: media.relations@novartis.com   Novartis Investor RelationsCentral investor relations line: +41 61 324 7944E-mail: investor.relations@novartis.com

WISeSat Signs a Service Agreement with Astrocast to Allow Access to Astrocast’s Operational Satellite Constellation - ForexTV

FOR IMMEDIATE RELEASE WISeSat Signs a Service Agreement with Astrocast to Allow Access to Astrocast’s Operational Satellite Constellation Geneva, Switzerland – June 25, 2025 – WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, today announces that its subsidiary, WISeSat.Space, a provider of secure satellite communications and space infrastructure, signed a strategic collaboration agreement with Astrocast, a Swiss-based nanosatellite IoT network operator, under which WISeSat will be gaining access to the operational satellite constellation of Astrocast. This collaboration significantly expands WISeSat’s existing operational satellite connectivity as Astrocast operates one of the largest LEO satellite networks in Europe. This agreement marks a major step in WISeSat’s mission to build a fully sovereign and secure European space ecosystem, aligned with EU space autonomy goals and ambitions. The expanded constellation access will strengthen connectivity, resilience, and coverage for Internet of Things (IoT) and critical infrastructure services across Europe and other strategic global regions. Carlos Moreira, CEO of WISeKey and WISeSat.Space, stated: “This is a decisive moment for the future of secure space communications in Europe. By utilizing Astrocast’s operational constellation, WISeSat’s is not only expanding its orbital reach, but it is also reinforcing Europe’s strategic autonomy in space. This partnership allows us to deliver more robust, real-time, and cyber-secure satellite-based services across key industries and geographies. It’s a powerful example of how Swiss-led innovation can shape the future of a sovereign, digital Europe.” This service agreement with Astrocast will support WISeSat’s secure IoT and communication services, which are powered by WISeKey’s cybersecurity and digital identity technologies, and deployed across sectors such as agriculture, environmental monitoring, logistics, energy, and defense. Fabien Jordan, CEO of Astrocast, added: “After a very challenging period of restructuring, the Astrocast constellation remains very reliable. We are excited to make this unique network usable for WISeSat and to help them shape the future of secure European space related services. This partnership demonstrates the power of collaboration in advancing innovation and delivering high-value, satellite IoT solutions.” This agreement also paves the way for deeper cooperation in areas such as edge AI in space, post-quantum cryptography, and satellite cybersecurity, further cementing Europe’s leadership in next-generation space technology. About Astrocast Astrocast SA operates a global nanosatellite IoT network, enabling reliable and cost-effective connectivity for remote and underserved regions. With a strong focus on innovation, Astrocast’s technology supports a wide range of industrial and environmental applications. About WISeSat.Space WISeSat.Space, a subsidiary of WISeKey International Holding Ltd (SIX: WIHN, NASDAQ: WKEY), provides secure satellite infrastructure designed to support sovereign European communications, IoT services, and critical mission applications. Its constellation of small satellites ensures end-to-end security and data sovereignty across strategic sectors. About WISeKey WISeKey International Holding Ltd (“WISeKey”, SIX: WIHN; Nasdaq: WKEY) is a global leader in cybersecurity, digital identity, and IoT solutions platform. It operates as a Swiss-based holding company through several operational subsidiaries, each dedicated to specific aspects of its technology portfolio. The subsidiaries include (i) SEALSQ Corp (Nasdaq: LAES), which focuses on semiconductors, PKI, and post-quantum technology products, (ii) WISeKey SA which specializes in RoT and PKI solutions for secure authentication and identification in IoT, Blockchain, and AI, (iii) WISeSat AG which focuses on space technology for secure satellite communication, specifically for IoT applications, (iv) WISe.ART Corp which focuses on trusted blockchain NFTs and operates the WISe.ART marketplace for secure NFT transactions, and (v) SEALCOIN AG which focuses on decentralized physical internet with DePIN technology and house the development of the SEALCOIN platform.Each subsidiary contributes to WISeKey’s mission of securing the internet while focusing on their respective areas of research and expertise. Their technologies seamlessly integrate into the comprehensive WISeKey platform. WISeKey secures digital identity ecosystems for individuals and objects using Blockchain, AI, and IoT technologies. With over 1.6 billion microchips deployed across various IoT sectors, WISeKey plays a vital role in securing the Internet of Everything. The company’s semiconductors generate valuable Big Data that, when analyzed with AI, enable predictive equipment failure prevention. Trusted by the OISTE/WISeKey cryptographic Root of Trust, WISeKey provides secure authentication and identification for IoT, Blockchain, and AI applications. The WISeKey Root of Trust ensures the integrity of online transactions between objects and people. For more information on WISeKey’s strategic direction and its subsidiary companies, please visit www.wisekey.com. DisclaimerThis communication expressly or implicitly contains certain forward-looking statements concerning WISeKey International Holding Ltd and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of WISeKey International Holding Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. WISeKey International Holding Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of the Swiss Financial Services Act (“FinSA”), the FinSa's predecessor legislation or advertising within the meaning of the FinSA. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey.Press and Investor Contacts WISeKey International Holding LtdCompany Contact: Carlos MoreiraChairman & CEOTel: +41 22 594 3000info@wisekey.com Media ContactsWISeSat.Space – press@wisesat.spaceWISeKey Investor Relations (US) The Equity Group Inc.Lena CatiTel: +1 212 836-9611 lcati@theequitygroup.com

Share Buybacks, Acquisitions, Arms Industry: Strategic Pillars to 2027 - ForexTV

The share buyback programme for employees was approved at the Annual General Meeting held on December 10, 2024. Following approval, several months were required to prepare for the programme’s launch, due to the need to comply with a complex legislative and regulatory framework that ensures transparency and adherence to both internal and external rules. GEVORKYAN, a.s. announces the implementation of its share buyback programme for the period from June 24, 2025 to June 10, 2026. The sole purpose of this buyback is to distribute the company’s shares to to employees under the Employee Stock Ownership Plan (ESOP) in accordance with Article 5(2)(c) of the Market Abuse Regulation (MAR). The programme is also planned for key employees involved in ongoing acquisitions.  GEVORKYAN, a.s. continues to strengthen its market position by diversifying its customer portfolio and acquiring projects with a focus on the arms industry.    Media contact: Monika Erdely, Marketing Manager, marketing@gevorkyan.sk Attention: This document in no way constitutes an offer or invitation to sell or buy securities. The information contained in this document is for informational purposes only and we recommend that you contact the above-mentioned representative of GEVORKYAN, a.s. for context and clarification. The public offering of shares in the Czech Republic was made on the basis of a prospectus for the shares prepared pursuant to Regulation (EU) 2017/1129 of the European Parliament and of the Council on prospectuses, which is available on the website of GEVORKYAN, a.s. Vlkanová, Slovakia 26 June 2025